Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose. Krieter P, Gyaw S, Crystal R, Skolnick P. J Pharmacol Exp Ther. 2019 Apr 2. pii: jpet.118.256115. doi: 10.1124/jpet.118.256115. http://jpet.aspetjo...

Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report. Ward HB, Barnett BS, Suzuki J. Subst Abus. 2019 Mar 19:1-6. doi: 10.1080/08897077.2019.1573776. Abstract https://www.ncbi.nlm.nih.gov/pubmed/3...

Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial. Krupitsky E, Blokhina E, Zvartau E, Verbitskaya E, Liozn...

Naltrexone: A History and Future Directions. Srivastava B, Gold MS. Cerebrum. 2018 Sep 1;2018. pii: cer-13-18. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353110/

No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study. Latif ZE, Solli KK, Opheim A, Kunoe N, Benth JŠ, Krajc...

Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis Monica Bolton, Alex Hodkinson, Shivani Boda, Alan Mould, Maria Panagioti, Sarah Rhodes...